Johnson and Johnson developing next-generation COVID-19 vaccines against emerging variants: CEO Alex Gorsky
New Delhi: Johnson & Johnson is developing several next generation COVID-19 vaccines against the emerging variants of the coronavirus, Chief Executive Officer Alex Gorsky said on Thursday.
The drugmaker, which won the U.S. emergency use authorization of a one-shot vaccine last month, had previously said it was developing a second-generation vaccine that would target the variant first identified in South Africa. J&J is also working on a two-dose version of its vaccine.
Read also: J&J gets US CDC Advisory Committee Recommendation for single-shot COVID-19 vaccine
"We could be in a situation where you could either need a booster to maintain the durability (of protection against the virus) or you might need to have a next derivative of the current vaccine to address these variants as they develop", Gorsky said at a webinar by the Economic Club of New York.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.